In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Eli Lilly & Co (LLY), with a price target of $143. The company’s shares closed yesterday at $119.65, close to its 52-week high of $121.84.
Chen noted:
“The growth prospects for LLY’s key drugs — Verzenio — as well as its pipeline assets, especially in pain, are underappreciated, in our view. Valuation Summary We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $143. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $143. Risks Greater than expected brand and/or generic competition for Lilly’s key drugs/products.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.9% and a 39.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $126.67, implying a 5.9% upside from current levels. In a report issued on February 6, BMO Capital also assigned a Buy rating to the stock with a $129 price target.
See today’s analyst top recommended stocks >>
Eli Lilly & Co’s market cap is currently $126.7B and has a P/E ratio of 38.23. The company has a Price to Book ratio of 9.69.
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
